Roman Galetto,Agnes Gouble,Stephanie Grosse,Cecile Mannioui,Laurent Poirot,Andrew Scharenberg,Julianne Smith
申请号：
US15711289
公开号：
US10363270B2
申请日:
2017.09.21
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
